Regarding the CCL2/CCR2 axis, which plays a role in the recruitment in tumors, phase I and II clinical trials of anti-CCL2 antibodies (carlumab) were performed and completed in solid tumors (NCT00992186) [82] and metastatic prostate cancer (NCT01204996) [83], respectively, which showed no significant antitumor activity as a single agent. This evidence concerns the gene CCL2 and metastatic prostate carcinoma.